ANI Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $172M TTM FCF base; 10% growth yrs 1-5; 4% yrs 6-10; 10% discount rate; 3% terminal growth; $250.2M net debt; 21.43M shares outstanding.

Reasoning: ANI Pharmaceuticals combines a stable generics base with the fast-growing Cortrophin Gel rare-disease franchise; FY2026 guidance implies >20% revenue growth; higher discount rate reflects specialty-pharma regulatory/litigation risk; resulting value implies meaningful undervaluation versus the current ~8x forward P/E, directionally consistent with (though larger than) sell-side price targets.